US is about to sue TEVA on alleged price fixing

The United States is about to sue pharmaceutical Teva for making prohibited price agreements. That’s what Bloomberg’s press office writes based on insider information. The Israeli maker of generic medicines tried to keep the price of these medicines artificially high.

The step taken by American justice comes after Teva rejected a settlement proposal. With that settlement, Teva would have had to plead guilty and pay a fine.

An indictment of Teva would be the most important outcome of years of judicial investigation into generic drug makers. Five other companies settled and paid a total of $426 million in fines. Earlier this month, CEO of Teva, Kåre Schultz told that his company did not make any prohibited price agreements and that Teva would fight to prove his innocence.